Vemurafenib

Common brands: Zelboraf, Cotellic, Tafinlar, Pain Relief, Yervoy

Top reporter: Genentech, Inc.

Kinase Inhibitor [EPC]Corticosteroid [EPC]Programmed Death Receptor-1 Blocking Antibody [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Benzodiazepine [EPC]
11,910
Total Reports
3,312
Serious Reports
2,066
Death Reports
30
Reported Reactions
Death Report Ratio: High (17.35%)

Patient Demographics

Male
6,036
Female
4,679

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Vemurafenib.

# Reaction Reports % of Total
1 RASH 1,540
10.0%
2 DEATH 1,060
6.9%
3 ARTHRALGIA 1,037
6.7%
4 FATIGUE 1,030
6.7%
5 OFF LABEL USE 856
5.5%
6 DIARRHOEA 823
5.3%
7 NAUSEA 810
5.2%
8 DISEASE PROGRESSION 765
5.0%
9 PYREXIA 739
4.8%
10 ALOPECIA 558
3.6%
11 DECREASED APPETITE 532
3.4%
12 VOMITING 473
3.1%
13 PHOTOSENSITIVITY REACTION 412
2.7%
14 PRURITUS 386
2.5%
15 SUNBURN 373
2.4%
16 MYALGIA 354
2.3%
17 ASTHENIA 346
2.2%
18 NO ADVERSE EVENT 346
2.2%
19 HEADACHE 337
2.2%
20 ERYTHEMA 311
2.0%
21 INTENTIONAL PRODUCT USE ISSUE 258
1.7%
22 DRUG INEFFECTIVE 251
1.6%
23 METASTASES TO CENTRAL NERVOUS SYSTEM 243
1.6%
24 SQUAMOUS CELL CARCINOMA 239
1.5%
25 MASS 237
1.5%
26 SKIN PAPILLOMA 234
1.5%
27 ANAEMIA 229
1.5%
28 DYSPNOEA 219
1.4%
29 PAIN 217
1.4%
30 WEIGHT DECREASED 215
1.4%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.